VISTAGEN THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.00% for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-06-15
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2026 was 0.00%.
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -0.60%.
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -1.11%, a 322.00% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.50%, a 15.25% decline from fiscal 2022.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2026-03-31 | 0.00% 10-K · filed 2026-06-15 | |
| 2025-03-31 | -0.60% 10-K · filed 2026-06-15 | -1.03% 10-K · filed 2025-06-17 |
| 2024-03-31 | -1.11% 10-K · filed 2025-06-17 | 1.11% 10-K · filed 2024-06-11 |
| 2023-03-31 | 0.50% 10-K · filed 2024-06-11 | |
| 2022-03-31 | 0.59% 10-K · filed 2023-06-28 | |
| 2021-03-31 | 0.59% 10-K · filed 2022-06-23 | |
| 2020-03-31 | 4.71% 10-K · filed 2022-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |